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Growth hormone secretion from pituitary cells in chronic renal
in sufficiency
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Growth hormone secretion from pituitary cells in chronic renal insuf-
liciency. To examine whether growth hormone (GH) secretion is ad-
versely affected by chronic renal insufficiency (CR1), the GH secretory
response of dispersed anterior pituitary cells perifused with GH-
releasing hormone (GHRH) was investigated in 5/6 nephrectomized
(CR1, N = 18) and sham-operated (N = 18) rats. Two weeks after
nephrectomy, during a period of stable uremia, CR1 rats had signifi-
cantly higher serum concentrations (mean SEM) of urea nitrogen and
creatinine than sham rats, 16.8 1.4 mmol/liter (47 4 mg/dl) and 79.6
0.0 smol/1iter (0.9 0.0 mg/dl) versus 6.1 0.4 mmol/liter (17 I
mg/dl) and 35.4 0.0 j.mol/1iter (0.4 0.0 mg/dl), respectively (P <
0.0001). Incremental gains in body weight and nose to tail-tip length of
CR! rats over two weeks were also significantly depressed, 53.3 5.38
g (CR1) versus 87.0 3.78 g (sham; P < 0.0001) and 3.2 0.2cm (CR1)
versus 3.6 0.1 cm (sham; P < 0.05). The cumulative food intake as
well as food efficiency (g food consumed/g weight gain) were also
adversely influenced by the uremic state: food intake 304 I g (CR!)
versus 397 6 g (sham; P < 0.0001) and food efficiency 0.173 0.013
g/g of weight gain (CR!) versus 0.219 0.008 gIg of weight gain (sham).
No significant difference in GH secretory rate (ngIminIlO7 cells) was
found between the uremic and sham animals under basal conditions,
65.2 2.1 (CR1) and 67.9 2.2 (sham) or in response to GH-releasing
hormone, 282.8 42.4 (CR!) versus 306.2 42.6 (sham). The secretory
curves representing concentration-GH response were similar in both
groups of animals. This study provides direct evidence that the re-
sponse of pituitary cells to GHRH is preserved in moderate CR1 and
suggests that, at this degree of renal function reduction, any disturbance
of GH secretion must be due to dysfunctions other than the secretory
capacity of the pituitary gland itself.
Growth impairment is a typical feature of CR1 in children [1,
2]. Multiple factors including sustained metabolic acidosis,
mineral disorders, hormonal disturbances, and malnutrition are
involved in its pathogenesis [3, 4]. It is believed that low caloric
intake and abnormalities in growth hormone (GH) metabolism
play a major pathogenic role [5—8]. Improvement of the growth
rate has been obtained in children and animals with CRF from
the employment of caloric supplementation [9—111 and, more
recently, through the use of GH therapy [12—18].
Normal or high serum concentrations of GH [19, 20] and low
insulin-like growth factor I [21, 22] have been found in uremic
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individuals. The decreased serum somatomedin activity seen in
patients with CR1 may possibly be due to circulating inhibitors
related to the uremic state [23]. In addition, several reports
have suggested that GH secretion might be altered in humans
[24—28] and rats [26] in uremia. Enhanced [24] and depressed
[27] GH response following different stimuli, such as L-dopa,
hypoglycemia or GH-releasing hormone (GHRH), has been
demonstrated in CRF patients, but the influence of the uremic
state on pituitary GH secretion is still undefined.
The present study was designed to evaluate GH secretion in
CRF by using perifusion of dispersed anterior pituitary cells
with GHRH in 5/6 nephrectomized and control rats. This
represents the first direct examination of the effect of uremia
from CR1 on the GH secretory capacity of pituitary cells.
Methods
Animals
Male Sprague-Dawley rats weighing 120 5 g were obtained
from Charles River Laboratories (Wilmington, Massachusetts,
USA) and maintained in individual cages in an environmentally
controlled animal facility (12-hour light-darkness cycle, temper-
ature between 21 and 23°C). Animals were fed standard 23.4%
protein rat chow (Purina 5001, St. Louis, Missouri, USA) in a
powdered form. Both food and tap water were available ad
libitum. After their arrival and before surgery, rats were accli-
mated to the new environment for four days.
Experimental design
The experimental protocol was approved by Virginia Com-
monwealth University's Institutional Animal Care and Use
Committee.
After a four-day acclimation period, rats underwent either
two-stage 5/6 nephrectomy (CRF rats, N = 18) or sham surgery
(sham rats, N = 18). Nephrectomy was performed in two stages
[29, 30]. During the first stage (day 0), the left kidney was
exposed, decapsulated, and the upper and lower thirds of the
kidney were removed. The second stage was performed one
week later (day 7). The right kidney was exposed, decapsu-
lated, renal pedicle was ligated, and the kidney was excised.
Sham animals were treated in a similar way, including bilateral
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renal decapsulation, but no kidney tissue was removed. Surgi-
cal procedures were performed under anesthesia with pentobar-
bital (1.25 mg/l00 g body weight, intraperitoneal) and ketamine
(4 mgIlOO g body weight, intramuscular).
Fourteen days after either the second-stage nephrectomy or
second sham operation, the animals were lightly anesthetized
with methoxyflurane and sacrificed by decapitation (day 21).
Rats were weighed using an electronic balance on days 0, 7,
10, 14, 18 and 21. Rats' snout to tail-tip lengths were measured
on days 0, 7, and 21, while the animals were anesthetized. Food
intake was measured from days 7 to 21. Food efficiency was
calculated by dividing the weight gained (g) and the food
ingested (g) during the period of time the animals were in stable
CR! (days 7 to 21). At the time of sacrifice (day 21), blood was
collected and adenohypophysis, anterior tibial muscle, and the
liver were excised. Muscle and liver were weighed before and
after desiccation for 16 hours at 120°C to determine their water
content.
Serum urea nitrogen and glucose were measured by electrode
using an auto analyzer (Astra, Beckman Instruments, Inc.,
Brea, California, USA). Creatinine was determined by means of
a Beckman autoanalyzer (Beckman Instruments, Inc.). Choles-
terol and triglycerides were measured by enzymatic methods
using a bioanalyzer (Cobas, Roche Laboratories, Nutley, New
Jersey, USA). Albumin was determined by photometric tech-
niques with an Albumin Test Kit (DuPont Co., Wilmington,
Delaware, USA) and a Serometer Model 370 filter photometer.
Six repetitions were carried out in each of the two groups of
animals. The adenohypophysis of three rats were used for each
group in each repetition for a total of 36 rats. The continuous
perifusion of anterior pituitary cells was specifically performed
[31] in the present experiments as follows. After rapid decapi-
tation, the posterior lobe of the pituitary gland was gently
removed and the anterior pituitary was submersed in Earle's
Balanced Salt Solution (EBSS; Gibco, Grand Island, New
York, USA), and then diced. Fragments were incubated for 20
minutes in 10 ml EBSS with 0.2% (wt/vol) trypsin and 0.15 mg
DNAse (deoxyribonuclease-!, Sigma Chemical Co., St. Louis,
Missouri, USA) at 37°C. Fragments were washed with calcium-
and magnesium-free EBSS. Cell dispersion was completed by
gentle trituration with a 1.0 ml pipette (Pipetman, Rainin
Instrument Co., Woburn, Massachusetts, USA). Stranded
DNA was removed, and an aliquot of cells was taken to
determine the total number of viable cells by the trypan blue
exclusion test, using a standard hemocytometer. Cells were
then gently mixed with Bio-Gel P2 (200 to 400 mesh, Bio-Rad
Laboratories, Richmond, California, USA), which had been
preswollen overnight in normal saline. The pituitary cell-Bio-
Gel mixture was packed into 2.0 ml plastic syringes (Sabre
International Products Ltd., Reading, Berkshire, England,
UK), which served as the perifusion chambers. The chambers
were submersed in 37°C water bath, and perifusion was per-
formed with Medium 199 (Gibco), containing 0.25% BSA, 10
U/ml penicillin, 0.5 sg/m1 streptomycin, 187.5 nglml amphoter-
icin B, and 5 g/m1 gentamicin at a mean flow rate of approxi-
mately 0.43 ml/min. Cells were allowed to equilibrate to pen-
fusion conditions for four hours, at which time GHRH was
administered in 2.5 minute pulses at 30 minute intervals. The
concentrations of GHRH (human; 1-40; Bachem, Inc., Tor-
rance, California, USA), were 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, 10,
30, and 100 flM, and were applied in a random order. Eluate was
collected as five minute fractions and stored at —20°C until
measurement of GH.
Concentrations of GH in the eluate fractions were measured
by radioimmunoassay with reagents supplied by Dr. A. F.
Parlow and the National Pituitary Hormone Program of the
NIDDK. Anti-rat GH serum S-4 and GH reference preparation
RP-2 were used. All standards were assayed in triplicate.
Intra-assay coefficients of variation were 5.8% and 6.5% at 0.25
and 1.0 ng/tube, respectively, and the interassay coefficient of
variation was 8.3% at 0.6 ng/tube.
Data analysis
Data, expressed as mean SEM, on weight, length, food
intake, and food efficiency were compared by analysis of
variance. Statistical significance was considered at a P value
less than 0.05. GH response to GHRH was determined taking
into account the differences in flow rate and the number of cells
per column. Thus, the GH concentration in sg/liter (ng/ml)
measured in each fraction was converted to a secretory rate in
ng/min/107 cells. The secretory response to each concentration
of GHRH was calculated as the secretory rate above baseline
during the 30 minute period following administration of the
pulse GHRH. The baseline was determined using trough GH
levels between GHRH-stimulated secretory episodes in con-
junction with the first preinfusion concentration and last postin-
fusion concentrations of GH. The amount of GH secreted
above the baseline was calculated as the difference between the
absolute GH value after stimulation and the paired baseline
value. The sum of resulting differences (quantitative GH secre-
tion) was divided by the number of fractions (six 5-mm fractions
collected over a 30 mm interval following each GHRH pulse) to
obtain the final value for the GH secretory response. The
sequence of responses was then rearranged in concert with the
ascending order of administered GHRH concentration. The
concentration-response relationship between the GH secretory
rate and the log of the GHRH concentration was evaluated by
regression analysis.
Results
Serum biochemical data are summarized in Table 1. All
nephrectomized animals had reduced renal function, as re-
vealed by the serum urea nitrogen and creatinine concentra-
tions. Compared with the sham rats, CR! rats were hypercho-
lesterolemic and had significantly lower concentrations of
serum glucose.
CR! severely impaired the growth of the nephrectomized
rats. The weight of each group of rats at the time of the first
stage nephrectomy was 164.8 2.5 and 168.3 2.5 g for CRF
and sham groups, respectively. During the two week period
following the second stage nephrectomy, weight gain of stable
CRF rats was significantly lower than that of sham animals (53.3
4.5 vs. 87.0 3.7 g; P < 0.0001). The gain in nose to tail tip
length was also lower in the CRF group (3.2 0.2 vs. 3.6 0.1
cm; P < 0.05). Food intake of CRF animals was approximately
75% of that of sham rats (304 1 vs. 397 6 g; P <0.0001).
Food efficiency of CR1 rats was significantly (P < 0.005) lower
in the CR1 group (0.173 0.013 vs. 0.219 0.008). CR1 and
sham rats did not differ in their water content of muscle (75.8
0.1 vs. 75.9 0.2%) and liver (71.5 0.3 vs. 71.2 0.2%).
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Table 1. Serum concentrations of urea nitrogen (SUN), creatinine, cholesterol, triglycerides, albumin and glucose in 5/6 nephrectomized
(CR!, N = 18) and sham-operated (sham, N = 18) rats
SUN
mmol/liter
.Creatinine
mol/1iter
Cholesterol Triglycerides Glucose .Albumin
g/litermmol/liter
Rat group (mg/dl) (mg/dl) (mg/dl) (mg/dl)
CRF: Mean
SEM
16.8
(47)
1.4
(4)
79.6
(0.9)
8.8
(0.1)
2.02
(78)
.08
(3)
0.58
(51)
0.07
(6)
9.1
(163)
0.1
(2)
9
(0.9)
0
(0.0)
Sham: Mean
SEM
6.1
(17)
0.4
(1)
35.4
(0.4)
0.0
(0.0)
1.42
(55)
.05
(2)
0.75
(66)
0.07
(6)
9.8
(176)
0.3
(5)
9
(0.9)
0
(0.0)
P value <0.0001 <0.0001 <0.0001 0.10 <0.025 >0.25
Table 2
hormon
Concentration-response relationships between growth
e releasing hormone (GHRH) and growth hormone (GH)
release for continuously perifused pituitary cells
Group
Slope
ng/min/JO7cells Intercept
per nM GHRH ng/min/107 cells r2 P
Sham
CRF
88.2 7.7 308.5 23.0 0.71 0.0001
81.9 8.9 284.7 26.3 0.62 0.0001
Analysis of the perifusion study data demonstrated a similar
response in the pituitary cells from CR! and sham rats. In both
groups, the mean percentage of viable cells exceeded 95%.
Basal GH secretory rates were 65.2 2.1 and 67.9 2.2
ng/min/l07 cells for CR! and sham rats, respectively. Likewise,
there was no significant difference in the GHRH-stimulated GH
secretory rates. Both groups of animals showed a linear dose-
dependent concentration response (Table 2) as well as a similar
overall mean GHRH-stimulated GH secretory rate, calculated
as the sum of the responses to serial increments in GHRH
concentrations (282.8 42.4 and 306.2 42.6 ng/min/107 cells
for CRF and sham groups, respectively). Figure 1 illustrates the
two study groups' similarity in the GH secretory responses to
the ascending concentrations of GHRH doses.
Discussion
Renal insufficiency was produced in the 5/6 nephrectomized
animals, reflected by the mean serum urea nitrogen being
almost three times higher than that of sham rats. As a result of
CR! and diminished food intake, the nephrectomized rats had
hypercholesterolemia and a reduction in serum glucose concen-
trations compared to the sham animals. More importantly, the
degree of reduction of renal function in our nephrectomized rats
resulted in severe growth retardation and depressed food in-
take. The CR! rats not only ate less than sham animals, but,
moreover, had less efficient utilization of the food consumption.
Accordingly, incremental gains in weight and length were
significantly lower in the CR! group.
It is well established that circulating concentrations of GH
are frequently high in individuals with CR! [19, 201. The typical
pulsatile pattern of GH secretion makes the interpretation of
this finding difficult. Thus, despite decreased renal clearance of
OH in patients with low glomerular filtration rate [321, elevated
plasma OH concentrations in these CR! patients have usually
been attributed to abnormal regulation of pituitary GH secre-
tion rather than reduced renal elimination [25, 33]. However,
studies on GH secretion in CR! have been inconclusive and
have often led to contradictory results.
Clinical investigations to assess pituitary GH secretion in
CR! patients in response to conventional stimuli have yielded
no uniform results, with supra and subnormal responses being
reported [24, 27, 28]. Studies on pulsatile GH secretion have
suggested that GH secretion might be depressed in renal failure
[34], and a decreased pituitary content of GH has been reported
in uremic rats [26]. This might be explained by the presence of
high plasma concentrations of somatostatin, a potent inhibitor
of GH secretion, which has been found in patients with CR!
[35].
On the other hand, Phillips et al [23] initially reported the
presence of a circulating peptide of low molecular weight that
decreased somatomedin activity as assessed by stimulation of
CR1 means chronic renal insufficiency. Values for slope and intercept
are expressed as mean SEM. P values reflect the presence of linear
concentration-response relationships.
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Fig. 1. In vitro growth hormone (GH) secretory response of dispersed
pituitary cells from sham and chronic renal insufficiency (CR1) rats to
nine dfferent concentrations (nM) of GH-releasing hormone (GHRH).
GH release (mean 5EM) is expressed in ng/min/107 cells.
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sulfate uptake by hypophysectomized rat costa! cartilage in
vitro. Andress, Howard and Birnbaum [36] confirmed the
presence of a bone cell mitogenic inhibitor in uremic plasma,
and agree with a recent report indicating that it might actually
not be a peptide [371. The presence of high circulating levels of
a somatomedin inhibitory factor in uremia might influence GH
secretion by interfering with the well-known negative feedback
action of somatomedjn on GH secretion [34]. In this regard, the
potential for increased GH secretion might be related to the
increase in a somatomedin inhibitory factor. On the other hand,
high plasma concentrations of somatostatin, a potent inhibitor
of GH secretion, have been found in patients with CR! [35].
Our results are the first to present evidence on the ability of
pituitary cells in stable CR! to secrete GH at the basal state as
well as in response to incremental GHRH stimulation. Perifu-
sion of pituitary cells with GHRH is a reliable method of
assessing GH secretion [31, 38]. Therefore, although these in
vitro findings do not necessarily imply the same response of
pituitary cells in the in vivo uremic state, our results strongly
suggest that the GH response to GHRH is not disturbed in CR!.
It should be pointed out that the GH secretory rates of the
pituitary cells from CR1 animals were slightly, although not
significantly, lower than that of sham rats for all concentrations
of GHRH (Fig. 1). Accordingly, it cannot be ruled out that a
greater degree of uremia than obtained in our animals may still
impair pituitary GH secretion. However, it is also important to
note that, in the presence of normal GH secretory response, the
moderate CR! induced in the nephrectomized rats in our study
resulted in severe growth retardation, as assessed by inade-
quate weight and length gains.
CR1 rats consumed 25% less food than sham rats. Therefore,
interpretation of our results must require consideration of the
role played by malnutrition on pituitary GH secretion. Clinical
[391 and experimental [40] studies have shown impaired GH
release in malnourished individuals [39], and failure of serum
somatomedins to rise in response to GH injections has been
reported in nutritionally deprived rats [41] and humans [42].
Preliminary data from our laboratory indicate that there is no
difference in the GH secretion of perifused pituitary cells of 5/6
nephrectomized rats and pair-fed sham animals (unpublished
observations). Nevertheless, the interaction of malnutrition and
CR1 on GH secretion deserves further studies.
In conclusion, our study shows for the first time that pituitary
GH secreting capacity is preserved in rats with moderate CR1,
and suggests that peripheral circulating somatomedin inhibitors
and/or nutritional factors, rather than depressed responsiveness
of GHRH are responsible for the stunted growth of these
animals.
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